Published in Infect Immun on October 01, 2002
Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening. Infect Immun (2004) 1.25
Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun (2006) 1.22
Phenyl-alpha-tert-butyl nitrone reverses mitochondrial decay in acute Chagas' disease. Am J Pathol (2006) 1.21
Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines (2012) 1.21
Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection. Infect Immun (2006) 1.20
Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun (2003) 1.15
CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun (2005) 1.11
Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin (2011) 1.11
Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun (2004) 1.11
Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis (2011) 1.06
Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun (2007) 1.05
Phenotypic and functional characteristics of CD28+ and CD28- cells from chagasic patients: distinct repertoire and cytokine expression. Clin Exp Immunol (2004) 1.04
Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis (2010) 1.01
Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol (2008) 1.00
Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi. PLoS Negl Trop Dis (2011) 0.99
Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease. Infect Immun (2003) 0.98
The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development. J Parasitol Res (2012) 0.95
DNA Vaccines against Protozoan Parasites: Advances and Challenges. J Biomed Biotechnol (2007) 0.95
Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera. Parasit Vectors (2008) 0.94
ECG detection of murine chagasic cardiomyopathy. J Parasitol (2010) 0.94
A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease. Int J Biol Sci (2011) 0.93
A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog (2015) 0.92
Chagas' disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med (2010) 0.91
Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS One (2013) 0.88
Developments in the management of Chagas cardiomyopathy. Expert Rev Cardiovasc Ther (2015) 0.85
Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease. Clin Vaccine Immunol (2008) 0.84
Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS One (2013) 0.84
DNA immunization with Na+-K+ ATPase (Sseat-6) induces protective immunity to larval Strongyloides stercoralis in mice. Infect Immun (2005) 0.83
Effect of the plasmid-DNA vaccination on macroscopic and microscopic damage caused by the experimental chronic Trypanosoma cruzi infection in the canine model. Biomed Res Int (2013) 0.81
Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis. Parasitol Res (2009) 0.80
CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? Mediators Inflamm (2014) 0.80
A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi. PLoS Pathog (2015) 0.79
Antigen targeting to dendritic cells allows the identification of a CD4 T-cell epitope within an immunodominant Trypanosoma cruzi antigen. PLoS One (2015) 0.78
Prophylactic and therapeutic DNA vaccines against Chagas disease. Parasit Vectors (2015) 0.77
Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients. PLoS One (2015) 0.75
Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol (2007) 0.75
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells. Infect Immun (2016) 0.75
Exact prediction of a natural T cell epitope. Eur J Immunol (1991) 2.90
Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol Today (2000) 1.93
Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol (1997) 1.93
Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis (1999) 1.84
Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther (1998) 1.76
Parasite persistence in the aetiology of Chagas disease. Int J Parasitol (2001) 1.67
DNA vaccines. Life Sci (1997) 1.53
Chagas disease etiology: autoimmunity or parasite persistence? Parasitol Today (1999) 1.48
IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol (1996) 1.42
Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease. Infect Immun (1994) 1.38
Antigenic polymorphism of Trypanosoma cruzi: clonal analysis of trypomastigote surface antigens. Eur J Immunol (1984) 1.34
Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine (1998) 1.33
Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun (1998) 1.31
The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol (1998) 1.31
Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol (1997) 1.25
DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun (2001) 1.24
DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun (2000) 1.23
Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL. J Immunol (1998) 1.21
Predominance of CD8+ T lymphocytes in the inflammatory lesions of mice with acute Trypanosoma cruzi infection. Am J Trop Med Hyg (1993) 1.18
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun (1999) 1.13
Nucleotide sequence and transcription of a trypomastigote surface antigen gene of Trypanosoma cruzi. Mol Biochem Parasitol (1991) 1.13
Identification of immunodominant epitopes in Trypanosoma cruzi trypomastigote surface antigen-1 protein that mask protective epitopes. J Immunol (1994) 1.13
DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol (2001) 1.10
Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res (1999) 1.10
Measurement of cytolytic antibody in experimental Chagas' disease using a terminal radiolabelling procedure. J Parasitol (1980) 1.10
IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol (1999) 1.08
Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine (2001) 1.03
Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis. Infect Immun (1999) 1.03
Chagas disease: epidemiology and prospects for interruption of transmission in the Americas. World Health Stat Q (1992) 1.02
DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun (2001) 1.02
Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol (1998) 1.01
The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine (2001) 1.01
Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J Immunol (1999) 1.01
Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest (1998) 1.01
Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol (1999) 0.99
Molecular cloning of the gene encoding the 83 kDa amastigote surface protein and its identification as a member of the Trypanosoma cruzi sialidase superfamily. Mol Biochem Parasitol (1997) 0.95
The identification and molecular characterization of Trypanosoma cruzi amastigote surface protein-1, a member of the trans-sialidase gene super-family. Mol Biochem Parasitol (1997) 0.95
Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol (2000) 0.93
Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology (2000) 0.90
Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis (1995) 0.88
Malaria DNA vaccines in Aotus monkeys. Vaccine (1997) 0.87
Designer vaccines for parasitic diseases. Int J Parasitol (1997) 0.84
The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes. Mol Immunol (2001) 0.83
Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library of Trypanosoma cruzi. Vaccine (1998) 0.83
Augmentation of immune responses to hepatitis E virus ORF2 DNA vaccination by codelivery of cytokine genes. Viral Immunol (2000) 0.82
Modulation of immune responses to DNA vaccines by codelivery of cytokine genes. J Formos Med Assoc (1999) 0.79
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis (2004) 1.79
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol (2009) 1.17
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Res (2004) 0.88
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Multidimensional analysis of the insoluble sub-proteome of Oceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics (2007) 0.82
Multidimensional proteomic analysis of the soluble subproteome of the emerging nosocomial pathogen Ochrobactrum anthropi. J Proteome Res (2006) 0.80
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
A combined shotgun and multidimensional proteomic analysis of the insoluble subproteome of the obligate thermophile, Geobacillus thermoleovorans T80. J Proteome Res (2006) 0.78
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77